Clinical Trial Update: Combining Latency Reversing Agents to Address the HIV Reservoir [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update describing Phase 1/2 studies that combine latency reversing agents to tackle the HIV reservoir, with recruitment not yet started.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Snippet

Sponsor: Erasmus Medical Center | Conditions: HIV (Human Immunodeficiency Virus), HIV -1 Infection | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING